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Abstract: Osteoarthritis (OA) is a joint pathology characterized by progressive cartilage degradation.
Medical care is mainly based on alleviating pain symptoms. Compelling studies report the presence
of empty lacunae and hypocellularity in cartilage with aging and OA progression, suggesting
that chondrocyte cell death occurs and participates to OA development. However, the relative
contribution of apoptosis per se in OA pathogenesis appears complex to evaluate. Indeed, depending
on technical approaches, OA stages, cartilage layers, animal models, as well as in vivo or in vitro
experiments, the percentage of apoptosis and cell death types can vary. Apoptosis, chondroptosis,
necrosis, and autophagic cell death are described in this review. The question of cell death causality in
OA progression is also addressed, as well as the molecular pathways leading to cell death in response
to the following inducers: Fas, Interleukin-1β (IL-1β), Tumor Necrosis factor-α (TNF-α), leptin,
nitric oxide (NO) donors, and mechanical stresses. Furthermore, the protective role of autophagy in
chondrocytes is highlighted, as well as its decline during OA progression, enhancing chondrocyte
cell death; the transition being mainly controlled by HIF-1α/HIF-2α imbalance. Finally, we have
considered whether interfering in chondrocyte apoptosis or promoting autophagy could constitute
therapeutic strategies to impede OA progression.
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1. Osteoarthritis
Osteoarthritis (OA) is the most common chronic joint disease, affecting millions people worldwide.
OA incidence increases with age, and approximately 80% of the population displays radiographic
evidence of the disease after 65 years of age [1,2]. OA mainly causes pain, stiffness and mobility
difficulties, altogether leading to progressive disability and alteration of patient quality of life. Medical
care is mainly based on alleviating pain symptom using nonsteroidal anti-inflammatory drugs
(NSAIDs), and ultimately ends with joint replacement surgery [3]. Viscosupplementation has also
been recommended by the European Society for Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis (ESCEO). Intra-articular (IA) injection of hyaluronic acid can reduce pain and increase
function notably in the management of knee OA [4]. The etiology of OA is far from being well-known.
Its heterogeneity results from a combination of various risk factors and initiating mechanisms [5].
Accidental joint insult (i.e., trauma) can facilitate the development of OA and is, therefore, called
post-traumatic arthritis or secondary OA. Primary OA is associated with risk factors, identified and
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classified as non-modifiable (i.e., genetic and epigenetic factors, age, gender, and ethnicity) and
systemic (e.g., obesity) factors.
OA pathophysiology was, for a long time, attributed to biomechanical constrainst exerted on
weight-bearing articulations (e.g., knees, hips). However, metabolic factors are also well recognized as
mediators in the onset of OA [6]. Adipose tissue can act as an endocrine organ, releasing bioactive
molecules, such as pro-inflammatory cytokines (e.g., tumor necrosis factor-α,TNF-α) and adipokines
(Resistin [7,8], Visfatin [9], Leptin [10–12], and acute-phase serum amyloid a (A-SAA) [13]), of which
levels can be significantly and positively correlated with cartilage degradation in OA patients [14].
At the anatomic level, OA is characterized by a progressive breakdown of articular cartilage, involving
the remodeling of all joint tissues (bone, synovium, ligaments) with the appearance of osteophytes,
synovial inflammation, subchondral bone thickening, and in fine joint space narrowing [1]. Cartilage
degradation constitutes one of the prominent hallmarks of the disease.
Articular cartilage is a conjunctive tissue composed of only one cell type, chondrocytes, enclosed
in a self-synthetized extracellular matrix (ECM). These specific cells represent approximately 1% of
total cartilage volume and are responsible for matrix composition and integrity, thereby conferring to
cartilage its functions of mechanical support and joint lubrication [15]. Cartilage ECM is made of water,
collagens (essentially type II), aggregating proteoglycans, and hydrophilic macromolecules [16,17].
During OA development, progressive cartilage degeneration is observed. Histochemistry analyses
have demonstrated the formation of chondrocytes clusters, the presence of irregular surfaces
(fibrillations), cartilage volume loss, and matrix calcification in OA cartilage compared to normal
cartilage [18]. These changes in cartilage structure are linked to the alteration of molecular components
of ECM. Typically, the decrease in proteoglycan becomes prominent with disease progression and
can be evidenced by reduced Safranin-O staining [19]. Distribution of the collagen II network is
modified, being uniformly distributed throughout the normal cartilage layers, but at a decreased
level in OA-degenerated areas and at an increased level in chondrocytes clusters [18]. Breakdown of
these components are handled by a set of aggrecanases (e.g., a disintegrin and metalloproteinase with
thrombospondin motifs ADAMTS-4 and -5) and collagenases (e.g., matrix metalloproteases, MMP-1,
-3, -8, and -13), which are upregulated, even in early stages of OA-associated cartilage degradation.
Pro-inflammatory cytokines, such as IL-1β, TNF-α, and IL-6, are associated with OA occurrence and
participate in cartilage degradation through activation of pathways (e.g., nuclear factor-κB_NF-κB,
toll like receptor_TLR) that control MMPs and ADAMTS upregulation [20].
Chondrocytes are quiescent cells that rarely divide under physiological conditions: Adult human
cartilage is a post-mitotic tissue displaying virtually no cellular turnover [21]. Moreover, the ECM
is not innerved nor vascularizated, thereby avoiding new cell supply to compensate for potential
cellular loss. As a consequence, phenotypic stability, anabolic/catabolic balance activity, and survival
of chondrocytes are crucial for the maintenance of proper articular cartilage. During the course of OA,
all of these criteria are modified. Basically, Aigner et al. proposed classifying all chondrocytic changes
into five categories: (i) a phase of proliferation (early phase)/cell death (late phase); (ii) disturbed
anabolic synthesis activity; (iii) disturbed catabolic activity (chondrocytes that begin to overproduced
matrix degradative enzymes); (iv) phenotypic alterations; and (v) osteophyte formation (for an
extensive review, see Reference [22]). In the present review, we will focus on chondrocyte cell death and
its interplay with cartilage degradation and OA progression. Chondrocyte cell death was reported to
occur through apoptosis [23,24], chondroptosis [25], necrosis [26,27], autophagy [28], or a combination
of all these processes [26,29].
2. Cell Death Mechanisms
Cell death types are classified according to apoptosis (type I, see Section 2.1), autophagic cell
death (type II, see Section 2.3), and necrosis (type III, see Section 2.2) [30]. The current view is that
these different modes of cell death are not exclusive, but, rather, modulate each other through finely
tuned molecular crosstalk [31]. Table 1 lists key features of apoptosis, necrosis, autophagic cell death
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and chondroptosis, a specific cell death described in chondrocytes (see Section 3.1.5 for more details
on chondroptosis).
This table lists key features of apoptosis, necrosis, autophagic cell death as well as chondroptosis,
a specific chondrocyte death involving both apoptotic and autophagic components. This Table was
established based on informations collected from the following references: [25,32–36].
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Golgi apparatus No increase No increase Enlargement Increase in early stages
Autophagic
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involvement Yes No No Yes
ATP requirement Yes No Yes Not precised
2.1. Apoptosis
Morphological manifestation of apoptosis consists in cell shrinkage (while maintaining membrane
integrity), chromatine condensation at the perimeter of the nucleus, membrane blebbing, and,
ultimately, formation of apoptotic bodies containing putatively intact organelles [34]. In vivo, these
membrane-wrapped vesicles are quickly engulfed by resident phagocytes, thus preventing exposure
of intracellular components to the immune system and preventing inflammation [37].
In contrast to passive necrosis, apoptosis is a programmed cell death: At the molecular level,
apoptosis consists of sequential scheduled steps, including initiation, effector, degradation, and clearing
phases. Apoptosis belongs to normal cell cycle development and is regulated spatio-temporally
when cell death is needed at defined locations and precise steps (e.g., interdigital spaces formation,
endochondral ossification, ovaries regression) [38]. Apoptosis is also required in order to get rid
of infected, damaged, or abnormal cells to avoid any propagation [39]. However, excess or lack of
apoptosis can lead to pathological states, such as cancers or autoimmunity, underlying the importance
of careful control of this process.
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Depending on the stimuli, apoptosis can schematically take two main pathways, the death
receptor-mediated pathway (i.e., extrinsic) and the mitochondrial-mediated pathway (i.e., intrinsic)
(for an extensive review, see Reference [40]). Although the activation cascades differ, both intrinsic and
extrinsic pathway converge toward the activation of executioner caspases (i.e., mainly caspase-3, but
also caspase-6 and caspase-7) [41]. Caspase-3 is the most common executioner caspase, responsible
for the cleavage of numerous substrates, including cytokeratins, cytoskeletal, and nuclear proteins
(including Poly(ADP-Ribose) Polymerase (PARP) and the Inhibitor of Caspase-Activated DNAse
(ICAD)), leading in fine to a typical apoptotic dismantling of the cell through DNA fragmentation [42],
cytoskeletal reorganization, formation of apoptotic bodies, and phosphatidylserine (PS) exposure on
the outer leaflet of the plasma membrane [43], recognized by phagocytic cells for next uptake [44–46].
2.1.1. The Death Receptors Pathway (Extrinsic)
The extrinsic pathway is induced by damage or pathogen-associated molecular patterns (DAMPs
or PAMPs), and by cytokines activating the TNF superfamily of receptors. Death receptors belong
to the TNF superfamily of receptors. All receptors (about 30 different proteins) are type I single
passing transmembrane proteins, with the C-terminal part in the cytosol [47]. They are classified
into three groups, depending on the conserved domain present in the cytoplasmic tail: The death
receptor group includes eight members, known as TNF-receptor 1 (TNF-R1), Fas (also known as DR2,
APO-1, or CD95), TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), TRAIL-R2 (DR-5),
DR6, ectodysplasin A receptor (EDAR), and nerve growth factor receptor (NGFR) [48].
In the extrinsic pathway of apoptosis, engagement of the death receptor Fas by its ligand FasL
leads to the assembly of a typical multi-protein complex called the death inducing signaling complex
(DISC). DISC formation allows the recruitment and activation of initiator caspase-8, mediated by
the Fas-associated protein with death domain (FADD) adaptor molecule. Recruitment of caspase-8
leads to its autoproteolytic cleavage and subsequent activation [49]. Active fragments of caspase-8 are
released in the cytosol where they propagate apoptotic signal by cleaving and generating active effector
caspase-3 fragments that will further dismantle cell components [50]. Depending on the amount of
active caspase-8 generated by DISC, Fas engagement may require an amplification loop, including
Bid cleavage, formation of the apoptosome, and activation of caspase-9 prior to executioner caspase-3
activation [51].
2.1.2. The Mitochondrial Pathway (Intrinsic)
The intrinsic pathway is triggered in response to intracellular damage, cytokine withdrawal,
DNA damage, oxidative or endoplasmic reticulum (ER) stress, as well as cytosolic Ca++ overload [31].
These stimuli converge in mitochondrial outer membrane permeabilization, which is handled by
Bcl2 family members [52]. The activation of its initiator members (BH3-only members, e.g., Bid)
both inhibits its pro-survival guardians members (Bcl-2-like members, e.g., Bcl-2, Bcl-XL) and allows
the oligomerization of pro-apoptotic BH123 members (e.g., Bax, Bak), which thereby disrupt the
mitochondrial outer membrane. As a consequence, numerous proteins are directly released from the
mitochondrial intermembrane space into the cytosol. Amongst apoptogenic proteins, two classes
of proteins can be distinguished, those functioning independently of caspases (i.e., Omi/HtrA2,
apoptosis-inducing factor_AIF) [53] and those that activate caspases, either directly or indirectly
(e.g., Smac/DIABLO, cytochrome c_cyt c) [54]. Cyt c is the only known molecule able to activate the
apoptotic protease-activating factor-1 (APAF-1), a key component of the so-called apoptosome [55].
This multimeric structure is composed of Cyt c-bound oligomerized APAF1, and acts as a platform for
recruitment/activation of the typical initiator caspase of the mitochondrial pathway, caspase-9 [56].
In turn, activated caspase-9 can directly process downstream caspases-3/-6/-7, leading to substrate
cleavage and execution of apoptosis.
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2.1.3. Granzyme B Pathway
Granzyme B (GzB) is one of the most abundant granule serine proteases in mice and humans.
It is also the best-characterized protease, having its own proteolytic specificity and some of its
substrates have been elucidated [57,58]. Release of GzB is typically encountered in an immune
response context where natural killer (NK) and cytotoxic T cells degranulate. The delivery of these
cytotoxic proteases (including GzB) inside infected or transformed cells is mediated by the formation
of polyperforin-induced pores on cell membranes and ends with cell elimination. Once inside targeted
cells, GzB promotes apoptosis via two hierarchies of caspases activation: (i) the direct processing of
caspase-3 or (ii) the tBid/apoptosome/caspase-9-dependent cleavage of caspase-3.
In addition to caspases, GzB is able to cleave a wide array of substrates. It contributes to the
development of a plethora of diseases, including bone and joint diseases, such as Rheumatoid Arthritis
(RA) (reviewed in 2009 by Boivin et al. [58]). GzB specifically cleaves proteins from the ECM, such as
aggrecan, fibronectin, vitronectin, and laminin. In human RA chondrocytes, GzB expression was found
to be elevated compared to normal chondrocytes, as evidenced by semi-quantitative RT-PCR and
immunostaining [59]. Saito et al. also showed that isolated RA chondrocytes displayed NK cell surface
antigen, as well as NK cytotoxicity against NK-target K562 cocultured cells. Altogether, Saito et al.
proposed that, in RA cartilage, chondrocytes could undergo self-stocked-GzB-mediated apoptosis
and display cytotoxicity within affected cartilage [60]. The presence of granzymes A and B in the
synovium of OA patients was detected by PCR [61] although very little is known about the role of GzB
in OA onset.
2.2. Necrosis
Necrosis has been primarily defined as a passive, accidental cell death, caused by injurious stimuli,
such as heat, UV radiation, hypoxia, and cytotoxic anticancer drugs. Necrosis is morphologically
accompanied by cell swelling (oncosis), mitochondria swelling, cytoplasmic granulation, disruption of
the cytoplasmic membrane, and uncontrolled release of cellular contents (i.e., including lysosomal
enzymes, DAMPs, as well as a range of pro-inflammatory cytokines) into the intracellular space,
thereby exposing them to the immune system and creating an inflammatory reaction [62,63]. Digestion
of cell components is caspase- and energy-independent.
However, with time, the concept of regulated necrosis progressively emerged, since specific
cytokines, such as TNF-α, induced, in addition to classical apoptosis, morphological changes associated
with necrosis, depending on cell types [64]. Further, necrosis can also occur in physiologically relevant
situations (e.g., ovulation, immune defense, cellular turnover in the intestine, as well as the death
of chondrocytes controlling the longitudinal growth of bones [65]), and in pathological conditions,
such as epilepsy or Alzheimer’s disease [62].
Since then, multiple forms of regulated necrosis have been identified, such as necroptosis,
parthanatos, ferroptosis, (n)etosis, pyroptosis, and ischemia reperfusion injury (IRI)-mediated necrosis,
among which necroptosis is the best-characterized (for further review see Reference [31]). At the
molecular level, necroptic cell death results from an interplay between numerous signaling pathways,
in which RIP1 kinase seems to be a central initiator [62]. Some authors have also proposed that
caspase-independent necroptosis could be induced by pseudoachondroplasia-linked mutation of
COMP (D469del-COMP) in chondrocytes [66]. TNF-α was also found to induce rat chondrocyte death,
primarily via necroptosis, since necrostatin, but not z-VAD-fmk (caspase inhibitor), were able to reduce
propidium iodure (PI) uptake and inhibit TNF-α-induced chondrocyte death [67].
Discrimination between Apoptosis and Necrosis
Distinguishing apoptotic from necrotic cell death at the histological level may be difficult, as the
two processes can occur independently, sequentially, as well as simultaneously [68]. Moreover,
they share common inducers, as well as a common biochemical network, as evidenced by caspase
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knock-down studies. Indeed, caspase-8 knock-out did not prevent Fas-induced cell death, but, rather,
made the cell shift from apoptosis to necrosis, taking an alternate FADD and RIP-dependent pathway,
ending with an increased prevalence of necrotic cell morphology [69]. Theoretically, three major
commutators can convert an ongoing apoptotic process into a necrotic one: The intensity and duration
of the stimulus, the amount of disposable intracellular ATP, and caspases availability [68,70,71].
Various techniques are commonly used to discriminate apoptosis from necrosis. These are
based on (i) cytomorphological alterations (transmission electron microscopy_TEM); (ii) cell surface
markers of membrane alteration (phosphatidylserine exposure_AnnexinV) vs. membrane permeability
((PI) staining by flow fluorocytometry); (iii) oligonucleosomal DNA fragmentation (DNA laddering
in vitro or Terminal deoxynucleotidyl transferase biotin-dUTP Nick End Labeling (TUNEL) allowing
DNA strand breaks detection); (iv) caspase-3 activation, cleaved substrates (e.g., PARP), analysis
of caspases activator/inhibitors; (v) mitochondrial assays (e.g., mitochondrial membrane potential
(δΨm) quantified, for example, by J-aggregated fluorescence [72], Bid cleavage, cyt c release, Bax/Bcl-2
ratio) [40,73].
Taking the work of Grogan and coworkers [74] as an example, Aigner et al. suggested to use
multiple approaches to make conclusions regarding cell death type [75], especially in the cartilage
field, where apoptosis is a spaciotemporal multistep event [73]. In cell death research, TEM is the most
accurate method to identify ultrastructural changes imputable to apoptosis or necrosis (considered
as a golden standard). Although this expensive method does not allow large number of sample
analyses, it provides two- and three-dimensional images inside cells, allowing to understand biological
structure–function relationships at cellular, subcellular, and molecular levels [73,75]. In the case of
apoptosis, identification of true apoptotic bodies is achieved when a correlation can be made between
morphological appearance using TEM and TUNEL positivity [25]. As the presence of these corpses
reflect late phase of apoptosis, other techniques should be used in support.
Combining PS exposure measurements and PI incorporation (the well-known AnnexinV/PI
assay) can basically indicate early apoptotic engagement (PS+/PI−), since PS exposure precedes PI
incorporation whereas, in necrosis, both events coincide (directly PS+/PI+) [76]. However, based on
this method, depending on the time point considered, late apoptosis (PS+/PI+) can be confounded
with necrosis, emphasizing the importance of combining several methods of detection, caspase-3
activity measurement, or mitochondrial viability [74].
2.3. Autophagic Cell Death
Autophagy describes a cellular process consisting in the degradation of a damaged or superfluous
intracellular pool of proteins, carbohydrates, lipids, and organelles. It recycles the resulting breakdown
products that are further re-used by cells to generate new macromolecules or to produce energy and
maintain viability under nutrient stressing conditions (e.g., serum starvation, etc.). However, excess
autophagy can be deleterious and lead to cell death [77]. Three types of autophagy have been described
(i.e., macro, micro, and chaperone-mediated), and they differ in the mode of cargo delivery. Amongst
them, macro-autophagy is the most extensively studied and will be focused on in this review [78].
The autophagic pathway can be upregulated upon the integration of various signals, such as
hypoxia, ER stress, energy balance, cytokines, and growth factors [79,80]. The autophagic process occur
in successive steps, each of them controlled by the formation of a specific multiproteic complex [81].
During this process, the cargo (i.e., components targeted for recycling) is progressively surrounded by
a double-membrane until it is trapped in a spherical autophagosome. The autophagosome then fuses
with the lysosome, resulting in an autolysosome, where the cargo is digested by specific lysosomial
proteases [82], and the constituents are released and then re-used for biosynthesis or as sources of
energy [80].
About 35 different conserved autophagy-related genes (Atg) encode for the proteins involved in
the main steps of the macro-autophagy process [78]. Briefly, the initiation step requires the formation of
the first complex, Unc-51-like kinase 1/2 (ULK1/2)-ATG13-FIP200-ATG101, activated by mammalian
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target of rapamycin (mTOR) inhibition upon nutrient starvation [83]. The nucleation step further needs
the formation of a second complex, Beclin-1-Atg14-VPS34-VPS15 (also called the class III PI3K complex),
which results in the phagophore shaping around the cargo. Typical double-membrane elongation
and autophagosome achievement (enclosing the cargo) rely on the formation of two conjugates:
(i) ATG5–ATG12 conjugate, which associates with ATG16L and (ii) phosphatidylethanolamine (PE)
conjugated to LC3 (the microtubule-associated protein 1 light chain 3), the latter being the major
constituent of autophagosomes. LC3 cytosolic form (LC3I) is cleaved by ATG4 and is next conjugated
with PE by ATG7 and ATG3. This lipidated LC3 (LC3-II) then associates with newly-forming
autophagosome membranes. LC3-II remains on mature autophagosomes until its fusion with
lysosomes. The conversion of LC3-I to LC3-II is considered as a specific autophagy marker [84].
3. Apoptosis in Chondrocytes and Osteoarthritis (OA) Development
3.1. Apoptosis Incidence and Contribution to OA Development
Common situations involve chondrocyte apoptosis, such as the terminal differentiation of
hypertrophic chondrocytes from the growth plate (described in bird [85], pig [86], and rabbit [87]),
as well as pathological states involving mice and rat [88] or human [89–91] cartilage degeneration,
such as OA, or the ultra-rare alkaptonuria [92]. Histological data revealed lacunar emptying and
reduced cell density within osteoarthritic cartilage, suggesting that cell death could occur during the
OA process and even participate in OA onset [93]. Further studies showed that apoptosis effectively
occurred in OA cartilage more frequently than in normal cartilage [24,89,90], and that there was a
positive correlation between the number of apoptotic chondrocytes and equine [23] or human [91]
cartilage degradation/severity of OA. However, the frequency/rate of apoptotic cells observed in
situ, mainly by TUNEL staining in human OA cartilage, is highly variable between studies: 6% [90],
19% [89,91], and even 30%–88% [94]. Aigner et al. reached the lowest rate, identifying two lacunaes
containing true apoptotic bodies out of several thousand examined in OA cartilage samples (about
0.1%) [95]. The relative contribution of apoptotic cell death in OA pathogenesis is difficult to assess
due to several factors:
3.1.1. Experiment Type
The type of technique used in order to state the nature of apoptosis in cell death. Although many
studies agree that apoptosis occurs in chondrocytes, both in vivo and in vitro, when using conventional
methods to assess DNA fragmentation (TUNEL) or FACS analysis, it is rare to demonstrate the presence
of true apoptotic bodies using electron microscopy [25]. Moreover, positivity with a TUNEL assay
could encompass necrotic cells [96], meaning that making conclusions about apoptosis with only a
TUNEL assay might compromise the conclusions and lead to overestimation of the apoptosis rate [75].
Therefore, TUNEL should be complemented by TEM.
3.1.2. Kinetic Inconsistency
Because the morphological events of apoptosis are fast and would theoretically end with a quick
clearance of chondrocytes, a rate of apoptosis that is too high would not be consistent with the slow
kinetics associated with the establishment of a chronic disease, such as OA diseases. Therefore,
it may be too simple to limit apoptotic chondrocyte cell death as the main pathogenesis mechanism in
OA [21,95,97].
3.1.3. Spaciotemporality
The stage of OA disease, as well as the cartilage layers in which apoptosis occur, also seem
to be crucial. Indeed, in the early phase of OA development, chondrocytes proliferate, giving rise
to OA-typical clusters [98], whereas empty lacunae and hypocellularity are encountered in a later
phase [93,99]. Furthermore, as we will see in Section 4, in an early stage of OA in the superficial and
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middle zones of cartilage, autophagy is triggered to avoid cell death [29,100]. In later stages, both
the apoptosis and autophagy processes could be activated, converging on cell death, suggesting that
apoptosis, in some circumstances, could occur as a consequence of first line autophagy [29]. Moreover,
some studies restrict empty lacunae into the deep zone of cartilage [27,101], whereas apoptotic cells
were also detected in the superficial and middle zones [91]. Finally, in some mechanical stress models
expected to mimic trauma-induced OA, chondrocyte cell death can also occur through a combination
of apoptosis and necrosis [26,102].
3.1.4. Fate of Apoptotic Bodies
The question of clearance of apoptotic bodies was addressed because phagocytes are absent in
the avascular cartilage environment. Some have proposed that, having isolated chondrocytes from
degenerated rat cartilage, that phagocytosis could be handled by chondrocytes displaying a dedicated
phenotype (i.e., type II collagen+/CD163+), in which phagocytic activity was measured, suggesting a
role in the clearance of apoptotic and necrotic cells [103]. Hashimoto and coworkers demonstrated
that apoptotic bodies derived from chondrocytes, treated with sodium nitroprusside (SNP) or anti-Fas,
contained both nucleotide pyrophosphohydrolase (NTPPH) and alkaline phosphatase activities and
could precipitate Ca++ [104]. The authors proposed that apoptotic bodies might contribute to OA
pathogenesis by increasing cartilage calcification, as is observed with OA cartilage. Apoptotic bodies
could also turn on secondary necrosis in the absence of quick phagocytosis [25]. This phagocytic-free
environment also gave birth to the concept of chondroptosis.
3.1.5. Chondroptosis
Several teams analyzing cell death in mammalian growth plates in swine [105,106] and rabbits [65],
or in articular cartilage [107], observed condensed cells (also called dark chondrocytes) displaying
ultra-structural patterns that were distinct from conventional apoptosis. The term chondroptosis
was proposed by Roach et al. to describe this type of cell death, occurring in vivo, in hypertrophic
chondrocytes (at the vascular front of growth plate) and in dying chondrocytes inside articular
cartilage, free of phagocytes [25]. Chondroptosis shares common features with classical apoptosis,
such as caspase involvement [108], cell shrinkage, and condensed chromatin contained in the nucleus.
DNA is also likely to be cleaved, since chondroptotic cells are positive in a TUNEL staining assay [65].
Nevertheless, appearance of condensed chromatin in the nucleus is distinct: In chondroptosis,
chromatin is spread in patches throughout the nucleus, whereas, in apoptosis, chromatin is found at
the margins at the nucleus membrane and is aggregated in large masses. Concerning cytoplasmic
changes, drastic differences distinguish chondroptosis from apoptosis. Unlike the apoptotic process,
where no increase of organelles is observed, chondroptosis cell death leads to the prominent expansion
of the rough endoplasmic reticulum (RER) and the Golgi apparatus. In the chondroptic process,
elimination of a cell is phagocytosis-independent and consists of self destruction mediated by three
phenomena: (i) the increased ER and Golgi membrane create compartments where cytoplasmic
components and organelles are digested [35]; (ii) the formation of multiple autophagic vacuoles; and
(iii) the extrusion of cellular material into the lacunae space, leaving remnants and vesicular debris,
distinct from the apoptotic bodies formed during apoptosis. The final stage of chondroptosis leaves
the lacunae empty [25]. More recently, other studies have reported on morphological changes, similar
to chondroptosis, notably after trauma-induced cell death in human and porcine discs [109], as well as
in other cartilage-degeneration-linked diseases, such as the extremely rare alkaptonuria (AKU) [92].
3.1.6. Cause or Consequence
Numerous studies have reported the decrease number of chondrocytes with aging and OA
progression in cartilage [88,110,111], and such hypocellularity was hypothesized to be the consequence
of chondrocyte apoptosis [93]. Meanwhile, multiple studies, performed both in animals and humans,
established a positive correlation between the severity of cartilage damage and chondrocyte death by
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apoptosis [23,90,91,93,108,112,113]. However, it is sometimes difficult to delineate if chondrocyte cell
death is a cause or a consequence of OA, as was extensively reviewed recently by Zamli et al. [114].
3.2. Apoptosis as a Consequence of OA Progression
Studies of α1 integrin and type II collagen KO transgenic mice bring grist to the mill of apoptosis,
as a consequence of the loss of matrix interaction between chondrocytes and their pericellular matrix.
α1 KO mice spontaneously develop more severe cartilage degradation, which encompasses an
increased number of apoptotic chondrocytes compared to wild-type (WT) littermates [115]. Changes in
matrix composition, reflected by COL2 KO transgenic mice studies, also showed a higher chondrocyte
apoptotic rate compared to WT littermates. Indeed, thanks to various approaches (TEM, TUNEL,
Bcl-2 decrease), Yang et al. observed an increase of chondrocytes with typical apoptotic features
in COL2−/− mice femoral cartilage compared to WT cartilage, suggesting that matrix-lacking type
II collagen could not support the survival of chondrocytes [116]. A similar apoptosis, related to
signal loss with the matrix, has been described in other systems, such as in epithelial cells, and was
called anoikis [117]. Our laboratory found that integrin αV, β3, and β5 were upregulated during
OA chondrocyte dedifferentiation [118]. The αVβ3 complex was also upregulated at the surface of
dedifferentiated OA chondrocytes, compared to freshly-isolated OA chondrocytes [118]. Differential
integrin expression status might be crucial in sensitizing chondrocytes to cell death induced by the ECM
component. Indeed, type II collagen NH2-propeptide (PIIBNP) encompasses RGD motifs and was able
to deliver a death signal in cells expressing αVβ3/β5 complexes [119]. Moreover, looking at the severity
of cartilage damage and apoptotic rates, several studies support that matrix loss precedes chondrocytes
apoptosis [23,24,90,91]. Preliminary matrix disruption could also increase its permeability, rendering
chondrocytes accessible to apoptosis-inducers, such as nitric oxide (NO) or cytokines secreted by
surrounding cells, such as synoviocytes or other chondrocytes. In line with this, several studies have
reported that the presence of collagenases predispose chondrocytes to apoptosis [114]. Moreover,
in mice, a decline in autophagy-related proteins is observed with age and preceded cell death and
structural cartilage damage [120]. However, it is unclear whether cell death or structural damage
occurs after a decline in autophagy [120]. Cartilage degradation was also observed as a consequence
of autophagy downregulation in immortalized human chondrocytes (TC28a2) and primary human
chondrocytes [121].
Zamli et al. addressed the relevant question of causality, determining the temporal sequence
between apoptosis and matrix changes, using a guinea pig experimental model. Indeed, these animals
are known to spontaneously develop OA with age [110]. Chondrocyte apoptosis was significantly
correlated to cartilage damage and hypocellularity, suggesting that chondrocyte apoptosis is a late
event of OA [122]. Zamli et al. underlined that, unlike destabilization of the medial meniscus (DMM)
mice model of OA, in which apoptosis was observed in the superficial zone (SZ) and middle zone
(MZ), chondrocyte apoptosis in guinea pigs was confined to the deep zone of articular cartilage,
perhaps reflecting a different mode of OA induction [122]. Zamli and co-workers further demonstrated
that bone remodeling, via subchondral bone plate thickening, preceeded chondrocyte apoptosis and
cartilage degradation [123].
A recent study analysed the causal relationship between chondrocytes death and cartilage damage
using confocal microscopy, standard histology, genetically engineered mice, and DMM surgery [124].
Authors showed that mice whose chondrocytes had been killed (i.e., Diphteria Toxin A (DTA)-ablated)
before DMM surgery had significantly less cartilage damage than control mice. Although DMM
surgery causes ultimately chondrocytes death, it is the dysfunction of living chondrocytes (i.e., their
catabolic phenotype), not their death, that enhances cartilage damage following injury [124].
3.3. Apoptosis as a Cause of OA Progression
Chondrocytes apoptosis could also be a pre-requisite for OA establishment, as evoked by other
research. In human cartilage, apoptosis, as an initiation step for OA onset, comes from the observation
Int. J. Mol. Sci. 2016, 17, 2146 10 of 36
of an increase number of apoptotic chondrocytes [91], or a decrease in the number of chondrocytes [125],
or even an apoptosis-related gene perturbation [126] within relatively macroscopically-normal OA
cartilage. Similarly, normal Atg5 conditional KO mice, which develop OA faster than WT mice,
also display enhanced chondrocyte apoptosis at two months of development, whereas cartilage does
not even display OA-related signs. Bouderlique et al. believe that this early loss of chondrocytes
facilitates OA development with age, as the first signs of age-related OA appear only at six months [127].
Moreover, in animal studies, chondrocyte apoptosis in mechanically-compressed bovine cartilage was
detected at a lower pressure than that required to stimulate cartilage matrix degradation, suggesting
that chondrocyte apoptosis may, therefore, be an earlier response to tissue injury, preceding OA
features [128]. Finally, cellular remnants (either apoptotic bodies or remnants from chondroptosis)
present in the pericellular matrix or in the chondrocyte lacunae, could eventually release their contents,
including proteases, thereby contributing to matrix degradation.
In conclusion, although chondrocyte cell death occurs in OA and is associated with cartilage
degradation, it remains unclear if cartilage degradation comes before or after chondrocyte cell
death [114].
3.4. Chondrocytes Apoptosis in OA Compared with Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects multiple joints.
Proinflammatory cytokines and autoantibodies induce synovial hyperplasia and cartilage degradation,
ending up with progressive destruction of articular structures [129]. RA synovial fibroblasts are
characterized by a typical apoptosis resistance resulting in hyperplasia whereas increased frequency of
chondrocytes apoptosis is reported in RA [130]. Indeed, Kim et al. compared apoptotic chondrocytes
rate in normal vs. RA cartilage samples. They found that apoptotic chondrocytes were more frequently
detected in human RA cartilage than in normal (30% vs. 1%) as measured by TUNEL experiment [131].
Using TEM, authors did not find bona fide apoptotic bodies but they observed other features consistent
with apoptosis, like cells with chromatin condensation and volume shrinkage. Interestingly, Bcl-2
expression was significantly lower in RA compared to normal cartilage (23% vs. 43%). However,
no difference in Fas gene expression between RA and normal cartilage was observed [131].
Interestingly, numerous observations were consistent with higher level of chondrocytes apoptosis
in RA. Levels of NO [132] and of two apoptosis related genes (i.e., c-myc and p53) [113] were reported
to be increased in RA cartilage. In addition, several substances found abnormally elevated in RA
synovial fluid, such as pro-inflammatory cytokines (i.e., TNF-α, IL-1β and IFN-γ) [133], Stromal
cell-Derived Factor-1 (SDF-1) [134] or Immune Complexes (IC) [135] were also able to stimulate
chondrocyte apoptosis, contributing to cartilage destruction in RA. Recently, Advanced Oxidation
Protein Products (AOPPs) have been found accumulated in patients with RA [136]. AOPPs could
accelerate cartilage destruction in rabbit arthritis model [136] and could induce chondrocyte apoptosis
through the Receptor for Advanced Glycation End products (RAGE)-mediated, redox-dependent
intrinsic apoptosis pathway in a rat model [137]. In vitro, AOPPs induced human chondrocyte
death through a redox-dependent pathway, including RAGE-mediated, NADPH oxidase-dependent
ROS generation, poly (ADP-ribose) polymerase-1 (PARP-1) activation [138] as well as ER-dependent
signals [136]. Interestingly, exposure of human chondrocytes to AOPPs significantly increased
the production of catabolic factors such as COX-2, MMP-3 and MMP-13, also contributing to RA
progression [139]. Finally, osteopontin (OPN) was reported as a deleterious factor in RA. Indeed,
OPN induces chondrocytes apoptosis in RA mouse model whereas chondrocyte apoptosis can be
suppressed significantly in OPN-deficient mice [140].
Several substances demonstrated an anti-apoptotic function in rat chondrocytes. Indeed,
intra-articular injection of osteoprotegerin (i.e., via adenovirus-mediated osteoprotegerin vector
(Ad-OPG) reduces proteoglycan loss and prevents chondrocyte apoptosis in a collagen-induced
arthritis rat model) [141]. In vitro, amiloride (inhibitor of acid-sensing ion channels) provides
protection against acid-induced apoptosis in rat chondrocytes through the restoration of mitochondrial
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membrane potential and Bcl-2 mRNA level [142]. Interestingly, prolactin (PRL) inhibits apoptosis both
in vitro and in vivo [143]. In vitro, PRL inhibits the apoptosis of rat cultured chondrocytes in response
to a mixture of proinflammatory cytokines (TNF-α, IL-1β, and IFN-γ) by preventing the induction
of p53 and decreasing the Bax/Bcl-2 ratio through a NO-independent, JAK2/STAT3–dependent
pathway. In vivo, eliciting hyperprolactinemia in rats before or after inducing the adjuvant model
of inflammatory arthritis reduced chondrocyte apoptosis whereas proapoptotic effect of cytokines
cocktail was enhanced in PRL receptor–null mice [143].
Recently, autophagy also emerged as a key player in the pathogenesis of RA, affecting mainly
synovial fibroblasts, osteoclasts and CD4+ T cells function and behavior (for an extensive review,
see Reference [144]). By contrast with OA, no information has been reported about autophagy in
the chondrocytes of patients with RA [144]. Recently, arthritic hTNFα-transgenic mice transplanted
with bone marrow cells lacking Atg7 (i.e., via LysMCre-mediated knockout of Atg7) were protected
from TNFα-induced loss of proteoglycan and chondrocytes death, suggesting that autophagy might
play a role in both the progression of experimentally induced RA and regulation of chondrocytes
apoptosis [145].
Similarities and differences exist between OA and RA chondrocyte apoptosis. Indeed, as observed in
OA, increased chondrocytes apoptosis occurs in RA compared to normal cartilage [24,131]. As observed
by Aigner et al. in OA cartilage samples, Kim et al. failed to find true apoptotic bodies in RA cartilage
slices, suggesting similarities. However, Yatsugi et al. found a significantly greater number of In
Situ (IS)NEL-positive chondrocytes in RA cartilage compared with OA cartilage, suggesting that RA
chondrocytes are more prone to apoptosis than OA chondrocytes [113]. In rodent, studies showed that
the protective properties of osteoprotegerin relied on the blockade of chondrocyte apoptosis in both
OA [146] and RA [141] models, suggesting common regulation of OA and RA rodent chondrocytes
cell death.
Some key pro-inflammatory cytokines (TNF-α, IL-1β) or mediators (NO) are elevated in both
OA and RA serum/synovial fluids compared to normal, that may induce cell death in OA and RA
chondrocytes. However, some synovial fluid marker are more specific : For example, Programmed Cell
Death PDCD5 levels in RA patients were significantly higher than those in OA and healthy controls
and might regulate chondrocytes fate in RA [147].
By contrast to OA, RA is an autoimmune-mediated inflammatory disease. Malemud et al. pointed
out the ”apoptosis duality“ occuring in RA. Indeed, the elevated frequency of chondrocyte apoptosis in
RA cartilage is opposed to the “apoptosis-resistance” observed in RA synovial tissue, where aberrant
survival of activated immune cells, macrophages, monocytes, dendritic cells and synovial fibroblasts is
encountered [130]. Therefore, any therapeutic strategy based on the inhibition of chondrocyte apoptosis
in RA would lead to a simultaneous aberrant survival of synovial fibroblasts and activated cells of the
immune system [130]. One possibility to achieve the dual objective of inhibiting chondrocyte apoptosis
while also impairing the aberrant survival of activated immune cells would be to simultaneously inhibit
the pro-survival PI3K/Akt/mTOR-signaling pathway [148]. Malemud et al. also emphasized the
need for studies assessing the level of chondrocyte apoptosis following administration of experimental
drugs or approved therapies for RA (e.g., anti-TNF) in well-validated animal models of RA [130].
Finally, by contrast with OA, no information has been reported about autophagy in the
chondrocytes of patients with RA. To our knowledge, only one study suggests that autophagy might
play a role in both the progression of experimentally induced RA and regulation of chondrocytes
apoptosis [145].
4. Autophagy in Chondrocytes and OA Development
Autophagy is an essential component of chondroptosis and, in excess, it can also lead to
autophagic cell death in chondrocytes. However, autophagy can play a dual role in chondrocyte
fate, as compelling studies have converged on the cytoprotective role of autophagy in OA
development [100,121,149,150]. More precisely, it seems that the chondrocyte death process evolves
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during OA progression and depending on the cartilage layer considered [29]. Chang et al. showed
that rapamycin (a potent autophagy inducer) could protect young chondrocytes, whereas excessive
activation of autophagy led to autophagic cell death in OA chondrocytes in vitro [28]. Almonte-Becerril
et al. demonstrated that during the early stage of OA, autophagy could be activated with the aim
of avoiding cell death in the superficial and middle zones, whereas in the late stage, both processes
could be activated, converging on cell death, as is described in chondroptosis [29]. In the deep zone,
no marker of autophagy were detected, whereas increased active caspase-3 and DNA degradation
were observed, suggesting that it is apoptosis that takes place in that zone, which is associated with
the abnormal calcification of cartilage observed in OA [29]. Accordingly, autophagy-related proteins
ULK1, Beclin-1, and LC3 were highly expressed in human chondrocytes clusters (encountered in the
early phases of OA development), whereas a reduced expression of these proteins was observed with
age, and were associated with increased apoptosis and decreased cartilage cellularity [100,120,151].
Several researchers strengthened knowledge of the protective role of autophagy against both
chondrocyte apoptosis and OA development. In a surgically-induced OA mouse model, Carames et al.
associated OA features with a concomitant loss of key regulators of autophagy, and with an
increase of apoptosis, as measured by PARP cleavage [120]. Moreover, silencing of beclin 1 resulted
in enhanced chondrocyte death [152]. Induction of autophagy (rapamycin-induced) abrogated
IL-1β-induced intracellular ROS production, possibly by removing damaged mitochondria, thereby
protecting chondrocytes from IL-1β-induced OA-like changes [151]. Recently, Lopez de Figueroa
et al. demonstrated that autophagy protected cells from mitochondrial dysfunction and apoptosis,
using the mitochondrial stressor oligomycin [150]. Olygomycin induced lower m∆Ψ, higher ROS
production, higher apoptosis with a lower LC3 puncta (i.e., dots visualized by immunofluorescence),
and higher mTOR activation suggesting that autophagy was defective in chondrocytes displaying
mitochondrial dysfunction. Restoration of autophagy by rapamycin and torin1 pretreatment impaired
oligomycin-induced apoptosis, as well as the decrease of ∆Ψ in chondrocytes, and provoked an
increase in LC3 puncta [150]. In line with this, treatment with rapamycin reduced the severity of
experimental OA [153]. An interdependence was observed between mitochondrial function and
autophagy, as Atg5-silenced chondrocytes induced mitochondrial dysfunction (i.e., ROS production
and m∆Ψ decrease) [150]. In line with this, mice bearing targeted deletion of Atg5 in chondrocytes
promoted the development of OA (according to OsteoArthritis Research Society International (OARSI)
scores) and an increase of chondrocyte apoptosis rate (as assessed by caspase-3 and -9 cleavage) at
two months of age [127]. Accordingly, autophagy could protect articular cartilage from OA, likely by
promoting chondrocyte survival. Overexpression of mTOR in OA, resulting from the inhibition of
autophagy in the articular cartilage, correlated with increased chondrocyte apoptosis and promoted
cartilage degeneration [154]. Vasheghani et al. went further, observing again increased apoptosis and
decreased autophagy in PPARγ inducible KO mouse models [155].
Autophagy Regulators in Chondrocytes: The Hypoxia Inducible Factors (HIFs)
The absence of blood vessels in articular cartilage restricts oxygen supply to passive diffusion
from synovial fluid and subchondral bone to chondrocytes [156]. An oxygen gradient was estimated
in cartilage, exposing chondrocytes of the joint surface to approximately 6%–10% O2 whereas
chondrocytes from the deepest layers of the articular cartilage may have access to only 1%–6%
O2 [157]. Adaptation to such a hypoxic environment is reported to be mediated by hypoxia-inducible
transcription factors HIF-1 and -2.
HIF-1 is a transcription factor known as a heterodimer, consisting of two different subunits,
HIF-1α and HIF-1β. Under normoxic conditions, the α subunit is degraded, whereas, under hypoxic
conditions, HIF-1α degradation is prevented and its accumulation is enhanced. HIF-1α, then,
translocates to the nucleus and further associates with its corresponding β subunit to form an active
HIF-1 transcription factor [158]. Interestingly, in chondrocytes isolated from normal or OA cartilages,
and cultivated in suspension under normoxic conditions, HIF-1α was detected in nuclear extracts
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whereas dedifferentiated OA chondrocytes did not express HIF-1α. Furthermore, HIF-1α was detected
in the nucleus of chondrocytes, in situ, in normal and OA cartilage sections [156].
The importance of HIF-1α for chondrocyte survival was brought about by transgenic studies,
revealing that HIF-1α conditional KO resulted in massive chondrocyte cell death (i.e., TUNEL
positivity) in the growth plate [159]. The mechanisms of cell protection may involve the modulation
of CDK inhibitor p57 expression, as p57 mRNA is absent in the HIF-1α−/− growth plate, and also
from vascular endothelial growth factor (VEGF) signaling [159]. In the growth plate, Bohensky et al.
showed that, prior to their apoptotic cell death, maturing chondrocytes survive in an autophagic state,
stimulated by HIF-1α [152]. The mechanisms of autophagy induction by HIF-1α could involve the
modulation of beclin-1/Bcl-2 complex [152], as well as the activation of the AMPK enzyme, resulting
in the inhibition of mTOR [160]. Hypoxia- and thapsigardin-induced autophagy share a common
HIF-1α-AMPK-mTOR axis of autophagic induction, since AMPK is activated in a HIF-1α-dependent
manner in response to thapsigardin in chondrocytes [160]. Recently, Zhang et al. supported the role of
Bcl-2 modulation in HIF-1α-mediated autophagy [161]. Hypoxia maintained chondrocyte phenotype
(i.e., measured as Sox9 and type II collagen mRNA increase associated with MMP-13 and ADAMTS5
mRNA decrease) and promoted autophagy (i.e., measured by ULK1 and ATG5 mRNA increase).
In parallel, hypoxia also increased miR-146a expression in a HIF-1α-dependent manner and miR-146a
promoted autophagy by decreasing Bcl-2 expression, an autophagy inhibitor [161].
In contrast, HIF-2α is a potent negative regulator of the autophagic flux [162] and plays a global
deleterious role in OA disease. HIF-2α mediates cartilage destruction, as well as chondrocytes
cell death, both contributing to the acceleration of OA progression [163]. To control cartilage
degradation, HIF-2α can upregulate the expression of matrix degradative enzymes, such as MMP-1,
-3, -9, -12, and -13, ADAMTS4, either directly by enhancing their promoter activities or indirectly
by cooperating with CCAAT/enhancer-binding protein β (C/EBPβ) [164], or inducing IL-6 [165] or
visfatin production [9]. HIF-2α also regulates the expression of other various catabolic factors, such as
type X collagen, VEGF, nitric oxide synthase 2 (NOS2), and prostaglandin-endoperoxide synthase 2
(PTGS2), thereby leading to cartilage destruction [166]. As mentioned below, HIF-2α is an apoptogenic
factor for chondrocytes via Fas promotion ([167], see Section 5.1.1), but is also a potent repressor of
autophagy and HIF-1α expression [162]. The link between HIF-2α and autophagy was primarily made
after observing that HIF-2α silencing resulted in the induction of autophagy. Indeed, HIF-2α-silenced
chondrocytes (N1511 mouse chondrocytes) displayed concomitant elevation of lysosomal activity,
a decrease of mTOR expression, and the presence of autophagosomes (visualized by TEM) [162].
5. Cell Death Regulators in Chondrocytes
5.1. Inducers
5.1.1. Fas-FasL
From rabbit-cartilage-based studies, Fas levels were reported to be higher in aged cartilage
and even correlated with decreased cellularity in articular cartilage during aging [168]. Fas levels
were also reported to be elevated in OA compared to normal cartilage [169], whereas other reports
showed similar staining in both cartilages [170]. These discrepancies may be due to the clone of
Fas antibody used, CH-11 [169] vs. UB2 [170]. Wei et al. and Hashimoto et al. agreed on the Fas
distribution in cartilage, was located within the superficial and middle zones, whereas it was absent in
the deepest layers.
Analyses of surface expression on chondrocytes isolated from normal and OA human knee
cartilages revealed no differences: About 30% of total cell populations expressed the receptor [170].
Agonistic Fas antibody was able to induce typical morphological apoptotic changes in isolated
chondrocytes, including in presence of NO synthesis inhibitor L-NMA, suggesting that Fas-induced
cell death was independent of NO production [170]. Further insights were obtained for Fas-induced
apoptosis, in vitro, with chondrocytes isolated from human normal knee cartilage. Fas-induced
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apoptosis was shown to rely on caspase-8 but not on caspase-9 activation [171], and Fas/FasL death
receptor expression and activity were markedly influenced by chondrocyte density [172]. The activity
of Fas was also found to be regulated by its glycosylation level in T cells [173], whereas, to our
knowledge, no information is available about Fas glycosylation status in chondrocytes.
In OA-cultured chondrocytes, using simultaneous PI vs. TUNEL or AnnexinV stainings to
discriminate necrosis vs. apoptosis, respectively, Wei et al. reported that Fas stimulation could induce
both types of cell death [169]. Apoptosis and necrosis could rely on p38, as p38 inhibitor SB203580
abolished Fas-induced cell death, caspase-3 cleavage, and even provoked chondrocyte proliferation.
However, Wei et al. did not confirm their observations using electron microscopy-based morphological
data. In OA cartilage, authors proposed that Fas stimulation occurred primarily via FasL derived from
the neighboring synovium because a significant amount of soluble FasL was found in the synovial
fluid of OA patients [174]. As Fas stimulation increased the production of FasL by OA chondrocytes,
Wei et al. suggested an amplification loop, facilitating the cell death process, by sustaining and
amplifying death signals [169]. Such a simultaneous occurrence of apoptosis and necrosis in an OA
context was previously reported in response to OA-mimicking impact damaged canine cartilage when
electron microscopy was performed [26].
The Fas/FasL system was also potentiated by other stimuli: HIF-2α [167], 4-hydroxynonenal
(HNE) [175], as well as actinomycin D (ActD) [176]. HNE is an end product of lipid peroxydation
(LPO). HNE is linked to joint pathology, in particular to OA, because HNE levels are increased in OA
synovial fluids, but also because it modulates type II collagen and MMP13 expressions in free radical
donors-treated OA chondrocytes [177]. HNE may also contribute to the altering of OA chondrocyte
viability by its ability to induce apoptosis, as reflected by caspase-3, -8, and -9-induced cleavage,
AIF and Cyt c mitochondrial release, PARP activation, and DNA cleavage [175]. The involvement of
Fas/FasL in HNE-induced apoptosis was suggested by two observations: The upregulation of Fas
(visualized by WB) in response to HNE stimulation, and the decrease in HNE-induced cell mortality in
chondrocytes pretreated with Fas antagonist [175]. Induction of the Fas/FasL system is also one of the
main target of hypoxia-induced factor-2α (HIF-2α, encoded by the Epas1 gene) to induce chondrocyte
apoptosis and cartilage destruction in mice models [167]. Indeed, HIF-2α was first described as a
deleterious factor in OA because heterozygous mouse Epas1+/− suppressed cartilage destruction in a
DMM mouse model of OA, whereas overexpression of HIF-2α in chondrocytes displayed spontaneous
cartilage destruction [166]. Few years later, it was demonstrated that HIF-2α-induced apoptosis relied
on the Fas/FasL activation system. HIF-2α overexpression upregulated Fas mRNA, as well as Fas
surface expression, as analyzed in FACS experiments. Moreover, HIF-2α-mediated apoptosis was
avoided in Fas-silenced articular chondrocytes, underlining the significance of Fas in HIF-2α-mediated
apoptosis. In vivo confirmation was obtained with a Fas-deficient mouse strain, which displayed
less chondrocyte apoptosis and less cartilage destruction after OA induction by DMM surgery or
Ad-HIF-2α-overexpression [167]. HIF-2α might also facilitate cell death through the inhibition
of autophagy [162] (see Section 4). Finally, chondrocyte cell death was increased when anti-Fas
was combined with actinomycin D or MG132 [176]. Kim et al. suggested that the sensitization of
chondrocytes to Fas treatment was mediated by p53 increase rather than by Bcl-2, Bax, FLICE inhibitory
protein (FLIP), or Fas ligand, of which expression levels were unaffected by MG132 or actinomycin
D [176].
5.1.2. Tumor Necrosis Factor-α (TNF-α) and Interleukin-1β (IL-1β)
Pathomechanisms of OA, reviewed in 2010, highlighted the role of proteins, such as HIF-2α [166],
MMP-13 [178], ADAMTS5 [179], discoidin domain receptor 2 (DDR2) [180], S100A8/9 [181],
and Syndecan-4 [182], which, once knocked down, alleviated or even suppressed OA features in
an OA mouse model [183]. Overexpression of these proteins, driven by IL-1β and TNF-α in OA
(117), led to a progressive loss of collagens and proteoglycans, disturbing cartilage structure and
affecting joint stability and function [20]. In addition to the upregulation of degradative enzymes by
Int. J. Mol. Sci. 2016, 17, 2146 15 of 36
chondrocytes, IL-1β and TNF-α also prevented the normal production of chondrocyte cartilage matrix
components (collagen type II and aggrecan) [184] and stimulated NO production (see Section 5.1.4),
thereby contributing, at least indirectly, to cartilage degradation and chondrocyte cell death. In line
with this, studies in OA animal models have also demonstrated the beneficial effect of anti-cytokine
therapy on chondrocytes [185,186]. However, the interplay and the precise roles of IL-1β and TNF-α
in chondrocyte cell death remain conflicting [187].
Indeed, on the one hand, some have stated that IL-1β alone failed to induce apoptosis in
chondrocytes [188], and others even attribute a preventative role to IL-1β in Fas-induced apoptosis,
relying on NF-κB activation and tyrosine phosphorylation [189]. Using DNA fragmentation and
caspase-3 processing techniques, IL-1β was able to enhance apoptosis in 16 out of 22 chondrocyte
samples, but not in the remaining six [132]. Some experiments have also showed that cell viability
was not modified by TNF-α or IL-1β in cultured chondrocytes, and that ActD was needed to facilitate
cell death [190]. The requirement of ActD for TNFα-induced apoptosis was also emphasized by
Yoshimura et al. [191]. As described in Section 5.1.4, IL-1β’s capacity to induce apoptosis would rely
on co-incubation with reactive oxygen species (ROS) scavengers [192].
On the other hand, IL-1β was described as an apoptogen in rat OA chondrocytes (as evidenced
by AnnexinV/PI staining, and caspase-8 and -3 cleavage) [193]. IL-1β could also indirectly induce
apoptosis through the upregulation of microRNAs (miRNAs), of which expression was reported in the
pathophysiology of various diseases, such as OA [194,195]. Some miRNAs (i.e., miR-34a, miR-146a,
miR-139, and miR-98) were involved in chondrocyte apoptosis: They were all overexpressed in OA
vs. healthy cartilage and their expressions were induced by IL-1β in OA chondrocytes (miR-34a [196],
miR-146a [197], miR-139 [198], miR-98 [199]) or in response to mechanical injury [200]. Concerning
the molecular mechanisms of miRNA-induced apoptosis, a recurrent pattern is the repression of
anti-apoptotic Bcl-2, as seen with miR-98 [199] and miR-139 [198], and, in some cases, the concomitant
upregulation of pro-apoptotic bax [196].
Similarly, TNF-α was also described as a potent inducer of apoptosis [201,202] whereas
Yoshimura et al. showed that TNF-α increased Bcl-2 synthesis in chondrocytes, and that cultured cells
were resistant to apoptosis using only TNF-α [191]. Our laboratory also previously demonstrated
that TNF-α markedly protects human primary chondrocytes from SNP-induced cell death through
NF-κB and Cox-2 [203]. Like IL-1β, TNF-α was able to induce apoptosis, but only in combination with
actinomycin D, as combined treatment reduced Bcl-2 synthesis and increased apoptosis in a dose- and
time-dependent manner [191]. Another study proposed TNF-α as an inducer of chondrocyte cell death
through a combination of apoptosis and autophagy. In this model, TNF-α caused the decline of protein
kinase CK2 activity, thereby promoting autophagy and facilitating apoptosis [204]. Emphasizing the
existing interplay between IL-1β and TNF-α, some studies showed that IL-1β-induced apoptosis could
also rely on TNF-α release, observed in rat OA chondrocytes, in response to IL-1β [193].
These puzzling data suggest that the pro-apoptotic or anti-apoptotic effects of IL-1β or TNF-α
may depend on the experimental model [190].
5.1.3. Leptin
A high prevalence of OA is observed in obese populations. According to metabolic theory,
white adipose tissue release of pro-inflammatory adipokines could participate in OA establishment.
Amongst them, leptin has been extensively studied and is considered as a key mediator of OA
progression. Leptin is produced, not only by adipocytes, but also by joint cells: Leptin expression
was found to be highly expressed in OA cartilage compared to normal cartilage [11]. Our laboratory
also described the molecular mechanisms of leptin production in OA synovial fibroblasts [205] and
OA chondrocytes [206]. We found that leptin expression is markedly enhanced by prednisolone,
is inhibited by genistein, and depends on the activation of Smad1/5 and the glucocorticoid-induced
leucine zipper (GILZ) [12,205,207]. Moreover, only dedifferentiated OA chondrocytes were able to
produce leptin compared to freshly-isolated primary chondrocytes [206]. Despite the fact that some
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authors have described an anabolic role for leptin in cartilage homeostasis, leptin was also suggested
to participate in cartilage destruction by its ability to induce the expression of multiple MMPs, ADMTS,
iNOS, or PGE2 (for an extensive review, see Reference [208]).
Compelling studies have also investigated the role of leptin on the apoptosis of chondrocytes
in OA, as well as the underlying mechanisms. In rat articular chondrocytes, leptin induced a
ROS-dependent apoptosis, perhaps by increasing lysyl oxidase-like (LOXL3) [209] and decreasing
dual specificity protein phosphatase 19 (DUSP19) [210] and uncoupling protein 4 (UCP4) [211].
All these downstream target of leptin were tested in a rat Anterior Cruciate Ligament Transection
(ACTL)-induced OA model, and their overexpression (UCP4 [211] and DUSP19 [210]) or
silencing (LOXL3 [209]) were found to attenuate/impede OA progression and chondrocyte
apoptosis. Interestingly, the silencing of LOXL3, in addition to inhibiting apoptosis, also promoted
autophagy [209]. In an in vitro model of OA, application of leptin to chondrocytes provoked
ROS and Janus-activated kinase-2 (JAK2)/STAT3-dependent-apoptosis [212]. By contrast, Lee et al.
showed that leptin had rather a protective role in vitro against TNF-α/CHX-induced cell death
in rat chondrocytes [67]. In line with this, leptin receptor KO mice (db/db) presented a deficit in
postnatal endochondral ossification. Db/db mice failed to regenerate bone in a fracture-healing
model [213]. Mesenchymal and endochondral ossification, normally required to regenerate bone
post-fracture, were impaired, probably partly as a consequence of the enhanced and premature
apoptosis of chondrocytes [213].
5.1.4. Nitric Oxide (NO) and Reactive Oxygen Species (ROS)
Unlike synoviocytes, chondrocytes display the capacity to produce nitric oxide. NO is a
multifunctional molecule that mediates dual role in chondrocytes. NO can be constitutively produced,
acting as a second messenger, and plays a critical role in cell proliferation, differentiation, and even in
protection against oxidative stress [214,215]. Some experiments have even shown that NO, by itself,
is not cytotoxic to cultured chondrocytes [214]. However, an overload of NO can be deleterious,
causing cartilage degradation [216] or inhibiting the synthesis of the cartilage matrix [217], provoking
mitochondrial dysfunction [72], and even resulting in cell death [72,192].
The link between NO and OA development has been emphasized by several observations.
A high level of NO was detected in synovial fluid from arthritis patients [218], and NO synthesis was
enhanced in OA cartilage [215]. Moreover, there exists a strong correlation between nitrite production
and apoptotic cell prevalence in cartilage harvested during experimentally-induced OA in rabbits [112].
Although NO was spontaneously produced by OA cartilage explants [219], several molecules were
found to increase NO production by chondrocytes through inducible nitric oxide synthase (iNOS)
upregulation, such as pro-inflammatory molecules (IL-1β, TNF-α, LPS) [220,221] or NO donors [219].
Nevertheless, the role of NO per se in the induction of apoptosis in chondrocytes is still subject to
debate and might depend on an upstream NO inducer (IL-1β or SNP).
On the one hand, Blanco and coworkers demonstrated that only NO could induce morphological
apoptosis in chondrocytes, whereas ROS (e.g., H2O2) further oriented cells toward necrosis.
Proinflammatory IL-1β, a prototypical inducer of endogenous NO, can also induce ROS production.
However, alone, IL-1β failed to induce chondrocytes apoptosis. Nevertheless, when incubated with
ROS scavengers, IL-1β was able to drive apoptosis [192]. It could be that IL-1β-induced ROS can react
with IL-1β-induced NO, avoiding the biologically active NO to induce apoptosis. Furthermore,
co-incubation of IL-1β and inhibitors of NO (e.g., N-Methyl Arginine, NMA) induced necrosis,
suggesting that the balance between ROS and NO could orientate the type of cell death [192]. Kim and
co-workers also proposed that IL-1β- and TNF-α-induced NO production was responsible for the
accumulation of mitochondrial DNA damage, therefore, playing a role in apoptosis of human normal
and OA chondrocytes [222]. NO from exogenous and endogenous sources induced apoptotic insults
to human chondrocytes via a mitochondria-dependent mechanism [223]. Meanwhile, the systemic
administration of iNOS inhibitor, N-iminoethyl-L-lysine (L-NIL), in experimentally induced OA in
Int. J. Mol. Sci. 2016, 17, 2146 17 of 36
dogs resulted in a reduction of articular cartilage damage as well as a decreased level of cell apoptosis
and caspase-3, as determined immunohistochemically [224].
On the other hand, the NO-donor SNP has been largely used to study cell death in cultured
articular chondrocytes [72,192,219,225]. Although NO generated downstream SNP was reported
to induce apoptosis in these cells, accumulating studies emphasized on the role of ROS-production
downstream NO in SNP-induced apoptosis. In this line, Del Carlo et al. concluded that NO-induced cell
death required ROS generation to occur in human cultured chondrocytes [214]. In rabbit studies, Liang
et al. also proposed that the co-production of ROS with NO could explain the cytotoxicity of SNP, since
ROS scavenger resveratrol avoided SNP-induced cell death [226]. Feeding this hypothesis, NOC12,
a more potent producer of NO than SNP, was less able to induce cell death compared to SNP [227].
Indeed, NOC12, although able to create mitochondrial dysfunction (i.e., decrease the mδΨ, and reduce
intracellular ATP level), failed to form apoptotic bodies in contrast to SNP [227]. In another study
analyzing human chondrocytes from various OA grades, SNP-induced cell death displayed features
of both apoptosis and necrosis [219]. Caspase-3 was not detected by immunoblotting experiments
using 0.2 to 1 mM SNP. SNP induced low levels of internucleosomal DNA fragmentation, as measured
by ELISA, whereas it causes extensive, large-scale degradation of nuclear DNA, as observed by
a TUNEL assay, independently of p38. This DNA degradation was profoundly inhibited in the
presence of NAC, a ROS scavenger, suggesting again the requirement of ROS in SNP-induced cell
death [219]. Accordingly, intra-articular injection of antioxidants, such as N-acetylcysteine (NAC) or
eicosapentaenoic acid (EPA), prevented cartilage destruction and apoptosis, in vivo, in a rat model of
experimentally-induced OA [228] or in a DMM mouse model of OA [229], respectively. SNP-induced
NO could induce cell death via the downstream production of ROS, NAC, neutralizing NO-induced
ROS in rabbit cultured chondrocytes. The apoptosis-preventing activity of NAC was mediated by
glutathione, as a glutathione synthetase inhibitor abrogated NAC protective effects [228]. In vitro,
EPA and NAC were able to reduce SNP-induced caspase-3 cleavage, as well as p53 [228,229] and p38
phosphorylation [229]. Other studies have supported that NO was not able to induce apoptosis, as the
production of high levels of endogenous NO (by adenoviral-mediated over-expression of the iNOS
gene) in adenoviral transfected chondrocytes failed to induce cell death [230].
The apoptosis signaling events leading to cell death after SNP treatment in chondrocytes
usually involves mitochondrial perturbation, such as reduction of mδΨ and Complex IV activity [72],
release of cyt c and AIF, cleaved Bid mitochondrial translocation [231], Bax and Bak activation [226],
as well as blockage of respiration and ATP generation in human articular chondrocytes and TC28
cells [232] and rabbit chondrocytes [233]. The latter studies suggested that mitochondrial perturbation
could contribute to matrix loss and cartilage mineralization, or to the inhibition of cartilage matrix
synthesis [232,233]. Interestingly, glucose level seems to also play a role in SNP-induced apoptosis.
Indeed, although Maneiro et al. showed that SNP-induced apoptosis via specific inhibition of Complex
IV, the inhibition of this complex (by NaN3) alone was not able to induce apoptosis unless it was
in association with glucose deprivation. Dependence on glucose levels for SNP-induced apoptosis
was also underline by de Andres et al., showing that the percentage of cell death after SNP treatment
decreased as glucose concentration increased [227]. This dependence on glucose was not observed
with another NO donor, NOC12 [227].
In human OA [225] and normal chondrocytes [72], SNP induced an increasing caspase-3
activity [225], or caspase-3 mRNA [72], associated with a reduction in the synthesis of the anti-apoptotic
Bcl-2 molecule [72,225]. Using a set of specific inhibitors, Notoya et al. showed that SNP-induced DNA
fragmentation and viability were dependent on ERK1/2 and p38 (whereas it was only dependent on
p38 in rabbit [234]), caspase-3 and -9, as well as on COX-2 expression. SNP treatment strongly induced
COX-2, which, in turn, mediated prostaglandin E2 (PGE2) production. PGE2 sensitizes chondrocytes
to apoptosis [225], but also mediates the anti-proliferative effect of IL-1-induced NO production in
chondrocytes [220], conferring to PGE2 a global inhibitory role in chondrocytes. Our previous work
showed that SNP induce apoptosis-like chondrocytes cell death characterized by a high molecular
Int. J. Mol. Sci. 2016, 17, 2146 18 of 36
weight DNA fragmentation and annexin V-FITC binding in human primary chondrocytes [203].
The proapoptotic effect of SNP was dependent on NF-κB. We also demonstrated that the NF-κB
inhibitor, BAY 11-7085, also induces high molecular weight DNA fragmentation [203] and chondrocyte
death [203,235]. BAY 11-7085 induced sustained ERK1/2 activation that was downregulated with
15-Deoxy-∆-12,14-prostaglandin J2 (15d-PGJ2). Of interest, both MEK/ERK inhibitor UO126 and
15d-PGJ2 protected human primary chondrocytes from BAY 11-7085-induced apoptosis [235].
In cultured rat chondrocytes, SNP-induced apoptosis seems to rely also on a perturbed Bcl-2/Bax
ratio, on p38 activation [231,236], as well as on cyt c and AIF release [231]. Interestingly, berberine and
cilostazol were able to inhibit SNP-induced apoptosis in vitro and displayed similar beneficial effect
in vivo. Indeed, in rat with experimentally-induced OA, intra-articular injection of berberine [236]
or oral administration of cilostazol [231] attenuated apoptosis of chondrocytes in vivo, increasing
the Bcl-2/Bax ratio, as well as diminishing TUNEL and caspase-3 positive cells in IHC experiments.
The protective effect was mediated by AMPK signaling activation and inhibition of p38 MAPK
activity [236].
In conclusion, although NO generation was involved in apoptosis induction under certain
conditions, it is unlikely that NO per se is the only mediator of cell death upon SNP treatment.
Other reactive species might contribute to its cytotoxicity, like the primary by-products of the
decomposition of SNP, such as the cyanide aninon or the pentacy-anoferrate complex or the reaction
product of NO and superoxide anions (i.e., peroxynitrite) [227]. Peroxynitrite was demonstrated to
trigger mitochondrial dysfunction, inhibiting mitochondrial Complexes I, II, and III [72], as well as
inducing calpain-dependent and caspase-independent cell death [237].
5.1.5. Mechanical Stresses
Traumatic joint injuries resulting from traffic accidents or sporting injuries constitute a known
risk factor for the development of secondary OA [238]. Several in vitro impact models have been
developed to study the molecular changes associated to trauma-induced OA: In vitro impact models
using instrumented drop tower [239], shear stress [240], or compression [128]. Mechanical stresses
applied to human cartilage explants [241] or to cartilaginous endplate chondrocytes [242] or to human
growth plate chondrocytes [243] result in chondrocytes apoptosis in vivo and in vitro [242] with
the associated loss of glycosaminoglycans, aggrecan, and type II collagen [241,244]. In contrast,
hydrostatic pressure was reported to increase matrix macromolecule expression [244]. Moreover, it is
also important to consider the intensity of the stress applied, which can induce either cell proliferation
or promote cell death [243].
Autophagy induction, post injury, is subject to debate, perhaps due to the animal model and the
type of injury applied. Indeed, in a rat model of biomechanically-induced degenerative cartilage of
the temporomandibular joint (TMJ), some have proposed that autophagy is induced as an early event
post injury, as observed by increased autophagosome detection by TEM, increased levels of beclin1
and LC3, as well as decreased mTOR and MAP4K3 activities [245]. In contrast, in bovine and human
cartilage explants subjected to mechanical impact, autophagy was inhibited, and rapamycin treatment
of mechanically-injured explants induced the expression of autophagy regulators and prevented cell
death and glycosaminoglycans (GAG) release [246].
Several reports propose a combination of necrosis and apoptosis in response to impact-damaged
canine cartilage [26]. Using the double staining Propidium Iodure (PI) (to stain dead cells)/Fluorescein
Di Acetate (FDA) (to stain living cells) on cartilage explants, whether loaded or not, Chen et al.
proposed that necrosis is an early event in impact-damaged cartilage, where apoptosis also occurred.
A combination of apoptosis and necrosis also occurred in a cartilage explant model, after blunt impact
at a 70% strain [102]. The same authors proposed that, depending on the intensity of trauma, different
death types occurred as they observed that a blunt impact above 80% strain resulted in necrosis [102].
With respect to the mechanistic, mechanical stress-induced apoptosis could be mediated by
MAPK and the mitochondrial apoptotic pathway in rat [242] and an increase of p38 phosphorylation
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in chondrocytes isolated from human normal and OA cartilages [247]. Oxidative stress has also
been underlined in various mechanical stresses, since antioxidants are able to reduce apoptosis
induced by shear stress [248] or abnormal cyclic loading [249]. Similarly, a decrease in antioxidant
capacity was evidenced in shear-stressed chondrocytes and contributed to their apoptosis [250].
At the signaling level, shear-induced COX2-inhibited PI3K, which in turn repressed antioxidant
response element (ARE)/NF-E2 related factor 2 (Nrf2)-mediated transcriptional response in human
chondrocytes [250]. Another study highlighted the role of COX2 as a downstream mediator of shear
strain, observing that COX2 inhibitors (celecoxib and indomethacin) could avoid shear-induced PGE2
release and apoptosis [239]. Authors concluded that treatments to prevent OA may include methods
of minimizing oxidative damage, whereas some others have suggested that a moderate oxidant
exposure could render chondrocytes more resistant to oxidative damage [251]. Shear stress induced
chondrocyte apoptosis (i.e., membrane PS exposure and nucleosomal degradation) [252] associated
with increased NO release [244,252] and modulation of Bcl-2 in OA chondrocytes [252]. Recently,
mechanical injury was also shown to cause apoptosis in human articular chondrocytes through
the upregulation of miR-146a, which controls VEGF overexpression and Smad4 downregulation
in vitro [200]. Similar VEGF upregulation and Smad4 downregulation was observed in vivo,
downstream of miR146a overexpression, in an experimentally-induced OA model [197].
5.2. Inhibitory Pathways
5.2.1. Wnt Signaling
Zhu et al. emphasized the protective role of Wnt pathway against chondrocytes apoptosis and articular
cartilage destruction. Indeed, the inhibition of β-catenin signaling in mice chondrocytes (i.e., using
Col2a1-ICAT–transgenic mice) resulted in a significant increase in articular chondrocyte apoptosis,
as identified by TUNEL staining, cleaved caspase 3 and PARP proteins immunostaining [253].
Consistently, Dkk-1 (a well-known inhibitor of Wnt/β-catenin pathway) induced chondrocyte
apoptosis in OA joints. Indeed, Dkk-1 expression was correlated with inflammatory cytokine levels
(IL-1β and TNF-α), pro-apoptosis mediators (Bad and caspase-3 expressions) and TUNEL staining in
human OA articular cartilage specimens [254]. Moreover, Dkk1 anti-sense treatment in ACTL-induced
OA rat model abrogated chondrocyte and osteoblast apoptosis as subchondral trabecular bone
remodeling in OA. Dkk-1 knockdown also decreased Bax in rat OA knee joint [255]. However,
function of Wnt pathway in chondrocyte homeostasis and OA pathogenesis remains controversial.
For example, Transcription Factor 4 (TCF4), a downstream mediator of Wnt/β-catenin signaling was
found elevated in human OA cartilage compared with healthy cartilage and may contribute to cartilage
degeneration in OA [256]. In addition, TCF4 overexpression activated caspase 3/7 and induced human
chondrocyte apoptosis (TUNEL measurement) [256].
5.2.2. Bcl-2 Signaling
Karaliotas et al. quantified mRNA expression of Bax and Bcl-2 from human normal and OA
cartilage tissue samples. The expression ratio of Bcl-2 /Bax was found to be significantly decreased
(2.76-fold) in the OA group compared with the normal cartilage control group (p = 0.022), suggesting
apoptosis induction [257]. Consistently, Bcl-2 gene transfection protected human articular chondrocytes
against nitric oxide-induced apoptosis [258]. Conversly, Bcl-2 was decreased after pro-apoptotic stimuli
(i.e., cytokine withdrawal and retinoic acid), suggesting that Bcl-2 plays an important role in the
maintenance of articular chondrocyte survival [259]. Similarly, repression of Bcl-2 is a recurrent pattern
for OA related miRNA-induced apoptosis (see Section 5.1.2). However, Kim et al. showed Bcl-2
expression was significantly elevated in OA lesional tissue as compared to non lesional cartilage [24].
Similarly, Iannone et al. reported that Bcl-2 was elevated in disease cartilage whereas Bax expression
was unchanged amongst normal, lesional or non lesional cartilage [260]. These observations might
suggest that Bcl-2 could regulate cell behavior independently from its control of apoptosis. Indeed,
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under cytokine withdrawal, constitutive expression of Bcl-2 maintained aggrecan level whereas Bcl-2
silencing resulted in aggrecan mRNA decrease in rat chondrocyte cell lines [261].
5.2.3. Insulin-Like Growth Factor-1 (IGF-1) Signaling
Insulin-like growth factor-1 (i.e., IGF-1) is an anabolic factor investigated for the treatment of
OA, notably in gene therapy clinical trials [262]. IGF-1 prevents apoptosis in chondrocytes [263]
through Bcl-2 [264] and MAPK/ERK pathway [265]. A recent study analysed the changes in
matrix production and gene expression following Adeno-Associated Virus (AAV)-mediated IGF-1
overexpression in equine chondrocytes [266]. Aggrecan and type II collagen were found significantly
induced whereas Bcl-2 transcript was unexpectedly decreased. As Bcl-2 expression vary in function of
the chondrocytes developmental stages, authors hypothesized that the decreased of Bcl-2 expression
might reflect a change from the late-proliferative and prehypertrophic phases to the resting phase
upon transduction [266].
5.2.4. TGF-β Signaling
TGF-β can transduce both ALK5/Smad2/3 or ALK1/Smad1/5/8 signals that have usually
opposing effects in cartilage. Indeed, signaling via Smad2/3 blocks chondrocyte terminal
differentiation but Smad1/5/8 signaling is strictly required for chondrocyte hypertrophy [267].
Typically, ALK1/ALK5 ratio is increased in aging and OA cartilage [268]. Therefore, understanding
the receptor balance in vivo is crucial for the resulting response [268]. TGF-β can play anti-apoptotic
role in chondrocytes. Venkatesan et al. monitored effects of rAAV-hTGF-β overexpression in human
normal and OA articular chondrocytes in vitro and in situ. TUNEL analysis showed that TGF-β
overexpression significantly and durably reduced the percentage of apoptotic cells in OA cartilage
compared with transduced control (36-fold decrease, p ≤ 0.001), bringing back the levels to those
observed in control normal cartilage [269]. The protective role of TGF-β was also demonstrated
indirectly. Indeed, miR-146a was identified as a miRNA differentially expressed in OA cartilage [270].
miR-146a specifically inhibits Smad4 and therefore, impaired the TGF-β signaling in cartilage. Jin et
al. proposed a pro-apoptotic role for miR-146a mediated by the inhibition of TGF-β pathway [200].
Mechanical pressure injury increased the expression levels of miR-146a and decreased Smad4 level in
human chondrocytes. Conversely, the knockdown of miR-146a reduced mechanical pressure-induced
apoptosis in chondrocytes and upregulated Smad4 expression [200]. Li et al. described miR-146a as
an IL-1β responsive miRNA, overexpressed in an experimentally induced OA rat model and able to
induce apoptosis in rat chondrocytes notably through Smad4 inhibition [197].
6. Targeting Chondrocyte Apoptosis for OA Treatment
Currently, there is no treatment for a full stop of OA progression. Therefore, preventing, limiting,
or delaying chondrocyte cell death, in order to maintain cartilage matrix integrity, might constitute a
tempting approach.
Caspase inhibitors (such as zVAD-fmk) are the most studied among all of the apoptosis regulators
in OA [97]. Notably, zVAD-fmk was tested in vivo in a rabbit Anterior Cruciate Ligament Transection
(ACLT) model of OA with a significant reduction of both chondrocyte apoptosis and cartilage
degradation [271]. However, Lotz et al. suggest that this strategy might be restricted to post-traumatic
arthritis [272]. Moreover, a tight control of the delivery site of these anti-apoptotic agent should be
required (limited to the cartilage injury site) in order to avoid the risk of systemic malignancies [21].
In addition, studies have shown that, in chondrocyte conditional caspase KO, chondrocytes shifted
towards necrotic cell death, suggesting that cells trying to avoid apoptosis paved the way for another
dying process, such as necrosis, if cells were programmed to die, whatever the way, depending on
caspase availability and ATP content [68].
Minimizing oxidative stress and preserving mitochondria integrity could constitute an alternative
approach. Antioxidants have demonstrated anti-apoptotic and anti-OA effects in rat and mouse
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models [228,229]. Promoting autophagy could also indirectly act on removing defective mitochondria
and the associated oxidative stress. Moreover, as key autophagic proteins were found to be decreased
in aging and OA cartilage, restoring autophagy could be considered to delay OA development. In this
sense, rapamycin prevented cell death and GAG loss, as well as a decrease in the expression of
ADAMTS5 in a mouse model of OA [153]. Meanwhile, as the long-term use of rapamycin could
trigger adverse events, increasing studies should aim at uncovering other molecules and signaling
pathways displaying an autophagy modulation function in chondrocytes [273]. Notably, glucosamine
was shown to be an effective autophagy activator both in vitro and in vivo [273]. Additionally, the
function and signaling associated with regulated in development and DNA damage responses 1
(REDD1), an endogenous mTOR inhibitor, was found to be decreased in aging and OA cartilage.
According to these findings, restoration of REDD1 can, not only result in autophagy activation, but
also improve mitochondrial function in chondrocytes [274]. Nevertheless, promoting autophagy has to
be considered cautiously, since it may also trigger the induction of apoptosis and, therefore, exacerbate
OA by accelerating cellular loss [77].
Targeting specific miRNAs may provide promising strategies for the treatment of OA: For example,
miR-142-3p constituted an anti-apoptotic molecule in vitro, and its overexpression impeded OA
progression in mice in vivo, indicating that miR-142-3p might be a potential molecular target for OA
treatment [275]. Conversely, miR-155, an inhibitor of autophagy, was found to be overexpressed in
OA: Developing an anti-sense strategy might contribute in restoring autophagy in chondrocytes [276].
Furthermore, preserving subchondral bone integrity could be an alternative strategy,
as subchondral bone plate thickening seems to be an early event in OA development, which preceded
apoptosis of chondrocytes in a longitudinal animal study [123]. Also, therapies dedicated to the
reduction of the catabolic phenotype of chondrocytes may protect against post traumatic OA [124].
A better molecular delineation of apoptotic and autophagic processes may help in designing new
therapeutic options for OA treatment.
7. Conclusions
In this review, we observed that apoptosis was linked to cartilage degradation and OA development.
However, apoptosis might not be the only cell death type encountered, and it is very likely that different
cell death types (i.e., apoptosis, necrosis, and chondroptosis) can occur independently, sequentially,
and even simultaneously, during OA process. The orientation toward cell death type might depend on
multiple parameters, such as the OA stage considered, the cartilage layer, the intensity and duration of
stimuli, the animal model studied, the in vivo/in vitro situation, as well as the availability of caspases
and ATP.
Although an excess of autophagy can lead to cell death, the current view is that the trigger of
autophagy in chondrocytes aims to avoid cell death, especially in the early stages of OA. The decline of
autophagy observed during OA progression relies mainly on the HIF-1α/HIF-2α ratio, emphasizing
them as major regulators of chondrocyte survival/death, skewing the balance toward autophagy
or apoptosis.
At the molecular level, chondrocyte cell death in response to Fas, SNP, proinflammatory cytokines,
and mechanical constraints delineate recurrent patterns, involving p38 activation, mitochondrial
dysfunction, Bcl-2/Bax ratio imbalance, and ROS production (see Figure 1).
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Figure 1. Molecular mechanisms of chondrocyte cell death. Chondrocyte death can be mediated by 
mitochondria dysfunction, Fas/FasL engagement, as well as by Nitric Oxide (NO) and Reactive 
Oxygen Species (ROS) production. p38 is often emphasized as a mediator of chondrocyte cell death, 
using various stimuli. Silencing of type II collagen or α1 integrin can cause chondrocyte cell death. 
Numerous miRNAs are IL-1β-responsive and play a role in osteoarthritis (OA) development and 
chondrocyte cell death. * The current view is that the trigger of autophagy in chondroctyes aims to 
avoid cell death, especially in the early stages of OA. However, the dotted arrow (depicted on the 
schema) emphasizes that excess autophagy can also lead to cell death. 
Figure 1. Molecular mechanisms of chondrocyte cell death. Chondrocyte death can be mediated
by mitochondria dysfunction, Fas/FasL engagement, as well as by Nitric Oxide (NO) and Reactive
Oxygen Species (ROS) production. p38 is often emphasized as a mediator of chondrocyte cell death,
using various stimuli. Silencing of type II collagen or α1 integrin can cause chondrocyte cell death.
Numerous miRNAs are IL-1β-responsive and play a role in osteoarthritis (OA) development and
chondrocyte cell death. * The current view is that the trigger of autophagy in chondroctyes aims to
avoid cell death, especially in the early stages of OA. However, the dotted arrow (depicted on the
schema) emphasizes that excess autophagy can also lead to cell death.
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